Cover Image
市場調查報告書

Acorda Therapeutics, Inc.:產品平台分析

Acorda Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226237
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
Acorda Therapeutics, Inc.:產品平台分析 Acorda Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年06月17日 內容資訊: 英文 48 Pages
簡介

本報告提供Acorda Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Acorda Therapeutics, Inc.的基本資料

Acorda Therapeutics, Inc.概要

  • 主要資訊
  • 企業資料

Acorda Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

Acorda Therapeutics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Acorda Therapeutics, Inc.:開發中產品概況

  • 後期開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Acorda Therapeutics, Inc.:藥物簡介

  • diazepam
  • capsaicin
  • dalfampridine ER
  • AC-105
  • NP-1998
  • cimaglermin alfa
  • rHIgM-22

Acorda Therapeutics, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Acorda Therapeutics, Inc.:最近的開發平台趨勢

Acorda Therapeutics, Inc.:暫停中的計劃

Acorda Therapeutics, Inc.:企業發表

Acorda Therapeutics, Inc.:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07182CDB

Summary

Global Markets Direct's, 'Acorda Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Acorda Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Acorda Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Acorda Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Acorda Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Acorda Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Acorda Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Acorda Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Acorda Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Acorda Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Acorda Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Acorda Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Acorda Therapeutics, Inc. Snapshot
    • Acorda Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Acorda Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Acorda Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Acorda Therapeutics, Inc. - Pipeline Products Glance
    • Acorda Therapeutics, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Acorda Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Acorda Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Acorda Therapeutics, Inc. - Drug Profiles
    • capsaicin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diazepam
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dalfampridine ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levodopa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cimaglermin alfa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rHIgM-22
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CVT-427
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Tenascin-C Fragments for Spinal Cord Injury
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Acorda Therapeutics, Inc. - Pipeline Analysis
    • Acorda Therapeutics, Inc. - Pipeline Products by Target
    • Acorda Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Acorda Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Acorda Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Acorda Therapeutics, Inc. - Recent Pipeline Updates
  • Acorda Therapeutics, Inc. - Dormant Projects
  • Acorda Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • AC-105
  • Acorda Therapeutics, Inc. - Company Statement
  • Acorda Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Acorda Therapeutics, Inc., Key Information
  • Acorda Therapeutics, Inc., Key Facts
  • Acorda Therapeutics, Inc. - Pipeline by Indication, 2015
  • Acorda Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Acorda Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Acorda Therapeutics, Inc. - Pre-Registration, 2015
  • Acorda Therapeutics, Inc. - Filing rejected/Withdrawn, 2015
  • Acorda Therapeutics, Inc. - Phase III, 2015
  • Acorda Therapeutics, Inc. - Phase II, 2015
  • Acorda Therapeutics, Inc. - Phase I, 2015
  • Acorda Therapeutics, Inc. - Preclinical, 2015
  • Acorda Therapeutics, Inc. - Pipeline by Target, 2015
  • Acorda Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Acorda Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Acorda Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Acorda Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Acorda Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Acorda Therapeutics, Inc. - Discontinued Pipeline Products, 2015
  • Acorda Therapeutics, Inc., Subsidiaries

List of Figures

  • Acorda Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Acorda Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Acorda Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Acorda Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Acorda Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Acorda Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Acorda Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top